RCM
SABS icon

Radcliffe Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Radcliffe Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-54,666
Closed -$5.52M – 1224
2021
Q4 		$5.52M Buy
54,666
+19,788
+57% +$1.86M 0.14% 135
2021
Q3 		$3.52M Sell
34,878
-122
-0.3% -$12.2K 0.1% 290
2021
Q2 		$3.49M Hold
35,000
– – 0.11% 307
2021
Q1 		$3.44M Buy
+35,000
New +$3.5M 0.14% 290

Other funds holding SABS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Radcliffe Capital Management's SABS Position: Q1 2022 in Review

Radcliffe Capital Management sold out of SAB Biotherapeutics (SABS) in Q1 2022, closing a stake of 54,666 shares — an estimated $5.52M sold.

Radcliffe Capital Management first reported a position in SABS in Q1 2021 and held it in 4 quarters. The position peaked at $5.52M in Q4 2021. 28 funds tracked by Wall St. Rank hold SABS as of Q1 2022.

  • Radcliffe Capital Management reported no remaining SAB Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Radcliffe Capital Management sold 54,666 SAB Biotherapeutics shares in Q1 2022, an estimated $5.52M.
  • Radcliffe Capital Management first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 4 quarters.
  • Radcliffe Capital Management's SAB Biotherapeutics position peaked at $5.52M in Q4 2021.
  • 28 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2022.

Based on Radcliffe Capital Management's 13F filing for Q1 2022, filed 16 May 2022.